Study reveals PGK1 enzyme as therapeutic target for deadliest brain cancer
Discovery of a dual role played by the enzyme phosphoglycerate kinase 1 (PGK1) may indicate a new therapeutic target for glioblastoma
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Discovery of a dual role played by the enzyme phosphoglycerate kinase 1 (PGK1) may indicate a new therapeutic target for glioblastoma
The European Commission, the European Parliament, experts and patients putting sarcoma on the political agenda
New mouse model gives researchers insight into rare form of triple-negative breast cancer
Paolo Casali presents an update of the latest evidence on the best way to manage sarcomas and gastrointestinal stromal tumours
Information for generalists on late effects of anticancer chemotherapy that may affect quality of life.
Rare tumour registry created to improve the outcomes of children with rare tumours
How can these cross-border healthcare structures improve the quality of care received by the almost half a million Europeans who are diagnosed with a rare cancer each year?
Glioblastoma patients with a protein called oncostatin M receptor on their tumours face a particularly poor prognosis
The event will take place at the EMA headquarters in London, UK, on 30 June 2016.
Too many teenagers and young adults are dying of some types of cancer, a Europe-wide report warns.
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.